First Trust Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.57M Buy
346,244
+254,902
+279% +$6.07M 0.01% 1166
2025
Q4
$2.13M Sell
91,342
-93,798
-51% -$2.09M ﹤0.01% 1856
2025
Q3
$3.65M Sell
185,140
-117,140
-39% -$2.41M ﹤0.01% 1538
2025
Q2
$6.56M Buy
302,280
+60,114
+25% +$1.42M 0.01% 1235
2025
Q1
$5.87M Sell
242,166
-1,991,668
-89% -$44.9M 0.01% 1237
2024
Q4
$46.6M Sell
2,233,834
-195,139
-8% -$4.19M 0.04% 545
2024
Q3
$48.3M Sell
2,428,973
-43,960
-2% -$815K 0.05% 515
2024
Q2
$38.3M Buy
2,472,933
+2,248,850
+1,004% +$35M 0.04% 570
2024
Q1
$3.57M Buy
224,083
+124,238
+124% +$1.87M ﹤0.01% 1463
2023
Q4
$1.68M Buy
99,845
+5,476
+6% +$74.9K ﹤0.01% 1791
2023
Q3
$1.1M Sell
94,369
-69,974
-43% -$936K ﹤0.01% 1931
2023
Q2
$2.21M Buy
+164,343
New +$2.36M ﹤0.01% 1653
2023
Q1
Sell
-167,435
Closed -$3.11M 2377
2022
Q4
$3.11M Buy
+167,435
New +$2.58M ﹤0.01% 1487
2022
Q3
Sell
-142,629
Closed -$1M 2494
2022
Q2
$1M Sell
142,629
-4,402
-3% -$32.3K ﹤0.01% 1986
2022
Q1
$1.22M Sell
147,031
-8,535
-5% -$60.3K ﹤0.01% 1977
2021
Q4
$1.05M Buy
155,566
+19,408
+14% +$128K ﹤0.01% 2032
2021
Q3
$722K Sell
136,158
-107,904
-44% -$590K ﹤0.01% 2154
2021
Q2
$1.4M Sell
244,062
-9,501
-4% -$49K ﹤0.01% 1948
2021
Q1
$1.17M Buy
253,563
+20,353
+9% +$80.9K ﹤0.01% 1937
2020
Q4
$779K Sell
233,210
-10,106
-4% -$34K ﹤0.01% 1992
2020
Q3
$723K Buy
+243,316
New +$951K ﹤0.01% 1900

Other funds holding CPRX

First Trust Advisors's CPRX Position: Q1 2026 in Review

First Trust Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 279% in Q1 2026, buying an estimated $6.07M and bringing the position to 346,244 shares worth $8.57M. The position accounts for 0.01% of the portfolio, ranked #1166.

First Trust Advisors first reported a position in CPRX in Q3 2020 and has held it in 21 quarters since. The position peaked at $48.3M in Q3 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • First Trust Advisors held 346,244 shares of Catalyst Pharmaceutical worth $8.57M as of Q1 2026.
  • First Trust Advisors bought 254,902 Catalyst Pharmaceutical shares in Q1 2026, an estimated $6.07M.
  • Catalyst Pharmaceutical made up 0.01% of First Trust Advisors's portfolio in Q1 2026, its #1166 holding.
  • First Trust Advisors first reported a position in Catalyst Pharmaceutical in Q3 2020 and has held it in 21 quarters since.
  • First Trust Advisors's Catalyst Pharmaceutical position peaked at $48.3M in Q3 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.